Uveal melanoma: No expression of HLA-G

Investigative Ophthalmology and Visual Science

Volumn 42, Issue 13, 2001, Pages 3081-3084

  Hurks, H Monique H ^a   Valter, Markus M ^a   Wilson, Louis ^b   Hilgert, Ivan ^a   Van Den Elsen, Peter J ^b   Jager, Martine J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA G ANTIGEN; HLA-G ANTIGEN; MESSENGER RNA;

ARTICLE; CELL CULTURE; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MELANOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UVEA TUMOR; WESTERN BLOTTING;

BLOTTING, WESTERN; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED; UVEAL NEOPLASMS;

EID: 0035653497     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kirszenbaum M, Djoulah S, Hors J, et al. HLA-G gene polymorphism segregation within CEPH reference families. Human Imminiol. 1997;53:140-147.
2. Colonna M, Navarro F, Bellon T, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med. 1997; 186:1809-1818.
3. Cantoni C, Verdiani S, Falco M, et al. p49, a putative HLA class I-specific inhibitory NK receptor belonging to the Ig superfamily. Eur J Immunol. 1998;28:1980-1990.
4. Rajagopalan S, Long EO. A human histocompatibility leucocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med. 1999;189:1093-1100.
5. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer receptors CD94/NKG2A, B and C. Nature. 1998;391:795-799.
6. Llano M, Lee N, Navarro F, et al. HLA-E bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol. 1998;28:2854-2863.
7. Carosella ED, Rouas-Freiss N, Paul P, Dausset J. HLA-G: a tolerance molecule from the major histocompatibility complex. Immunol Today. 1999;20:60-62.
8. Carosella ED, Dausset J, Rouas-Freiss N. Immunotolerant functions of HLA-G. Cell Mol Life Sci. 1999;55:327-333.
9. De Waard-Siebinga I, Houbiers JGA, Hilders CGJM, De Wolff-Rouendaal D, Jager MJ. Differential expression of HLA-A and -B on uveal melanoma as determined by immunohistology. Ocul Immunol Inflamm. 1996;4:1-14.
10. Blom DJD, Luyten GPM, Mooy CM, Kerkvliet S, Zwinderman AH, Jager MJ. Human leucocyte antigen class I expression: marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci. 1997;38:1865-1872.
11. Blom DJR, Schurmans LRHM, De Waard-Siebinga I, et al. HLA expression in a primary uveal melanoma, its cell line and four of its metastases. Br J Opmhalmol. 1997;81:989-993.
12. Zierhut M, Streilein JW, Schreiber H, Jager MJ, Ruiter D, Ksander BR. Immunology of ocular tumors. Immunol Today. 1999;20:482-485.
13. Ma D, Luyten GP, Luider TM, Niederkorn JY. Relationship between natural killer cell susceptibility and metastases of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci. 1995;36:435-441.
14. De Waard-Siebinga I, Blom DJ, Griffioen M, et al. Establishment and characterization of a uveal melanoma cell line. Int J Cancer. 1995; 62:155-161.
15. Lee N, Malacko AR, Ishitani A, et al. The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity. 1995;3:591-600.
16. Hurks HMH, Metzelaar-Blok JAW, Mulder A, Claas FHJ, Jager MJ. High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines. Int J Cancer. 2000;85: 697-702.
17. Cabestre FA, Lefebvre S, Moreau P, et al. HLA-G expression: immune privilege for tumor cells? Semin Cancer Biol. 1999;9:27-36.
18. Paul P, Cabestre FA, Le Gal FA, et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res. 1999;59:1954-1960.
19. Paul P, Rouas-Freiss N, Khalil-Daher I, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA. 1998;95:4510-4515.
20. Pangault C, Amiot L, Caulet-Maugendre S, et al. HLA-G protein expression is not induced during malignant transformation. Tissue Antigens. 1999;53:335-346.
21. Davies B, Hiby S, Gardner L, Loke YW, King A. HLA-G expression by tumors. Am J Reprod Immunol. 2001;45:103-107.
22. Frumento G, Franchello S, Palmisano GL, et al. Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by γIFN treatment. Tissue Antigens. 2000;56: 30-37.
23. Real LM, Cabrera T, Collado A, et al. Expression of HLA-G in human tumors is not a frequent event. Int J Cancer. 1999;81:512-518.
24. Cresswell AC, Sisley K, Laws D, Parsons MA, Renie IG, Murray AK. Reduced expression of TAP-1 and TAP-2 in posterior uveal melanoma is associated with progression to metastatic disease. Melanoma Res. 2001;11:275-281.
25. O'Callaghan CA. Molecular basis of human natural killer cell recognition of HLA-E (human leucocyte antigen-E) and its relevance to clearance of pathogen-infected and tumour cells. Clin Sci. 2000; 99:9-17.
26. Apte RS, Mayhew E, Niederkorn JY. Local inhibition if natural killer cell activity promotes the progressive growth of intraocular tumors. Invest Ophthalmol Vis Sci. 1997;38:1277-1282.
27. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol. 1998;160: 5693-5696.
28. Repp AC, Mayhew ES, Apte S, Niederkorn JY. Human uveal melanoma cells produce macrophage migration inhibitory factor to prevent lysis by NK cells. J Immunol. 2000;165:710-715.
29. Shimizu T, Ohkawara A, Nishihira J, Sakamoto W. Identification of macrophage migration inhibitory factor (MIF) in human skin and its immunohistochemical localization. FEBS Lett. 1996;381:199-202.